Oxygenta Pharma (524636)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth is still positive at 2.17%, showing the business hasn't collapsed entirely
• Latest quarter sales of ₹34 Cr indicate a small but existing revenue base
• Reported ROE of 85.30% could attract attention, though likely distorted by low equity
• Small market cap of ₹122 Cr may leave room for operational or financial restructuring

Concerns

• Latest quarter net loss of ₹5 Cr and profit growth of -23.16% show earnings deterioration
• ROCE of -24.93% means capital is being destroyed at the operating level
• Piotroski F-Score of 3/9 signals serious financial weakness
• Current price ₹32.25 is below the 52-week low of ₹45.30, indicating extreme negative momentum or data inconsistency
• No dividend and zero P/E provide no income or earnings support

AI Analysis

At ₹32.25, Oxygenta Pharma has a market cap of ₹122 Cr. But when I look at the numbers, I see a business losing money. The latest quarter shows sales of ₹34 Cr and a net loss of ₹5 Cr. Profit growth is -23.16%, and the Piotroski F-Score of 3/9 screams poor financial health. ROCE is -24.93%, meaning operations are destroying capital, not creating it. The ROE of 85.30% looks tempting, but with no book value and no debt/equity data, it is almost certainly a mirage from a tiny or negative equity base. There is no moat here. Sales growth of just 2.17% shows a business stuck in neutral. The current price sits at ₹32.25, below the stated 52-week low of ₹45.30, which tells me the market is rejecting this stock violently. Sometimes a falling price is an opportunity, but only if the business is sound. Here, the fundamentals are deteriorating—negative earnings, negative return on capital, and a F-Score of 3/9. P/E is zero because there are no earnings to speak of, and there is no dividend to reward patience. This is not a wonderful business at a fair price; it is a troubled business at a falling price. Ben Graham would demand a margin of safety in the balance sheet, and I don't see one. This could turn around one day, but I need proof of margin recovery, positive cash flow, and a cleaner capital structure before I even open a file on it. For now, this looks more like a value trap than a value investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer